Matthew J. Petruso; Samuel M. Philbrick
High-altitude aviation and airborne operations continue to carry a risk of decompression sickness (DCS), even when modern preventative protocols are followed. This risk is magnified in geographically remote locations where access to specialist medical facilities is limited. A case managed by the U.S. Air Force in Alaska demonstrates how portable hyperbaric capability can provide definitive treatment without reliance on long-range aeromedical evacuation.
Case Overview
Following a controlled high-altitude decompression flight in support of HALO jump operations, a female military pilot developed delayed-onset symptoms including headache and migrating joint pain. Although no symptoms were reported during flight, clinical presentation over the following 48 hours raised suspicion of neurological decompression sickness.
Under conventional pathways, definitive treatment would have required aeromedical evacuation to a distant fixed hyperbaric facility, involving significant cost, delay, and additional exposure to altitude-related risk. Instead, the patient was transported by ground to Eielson Air Force Base, where a portable monoplace hyperbaric chamber was available.
After consultation with a hyperbaric medicine specialist, treatment was initiated using a standard monoplace hyperbaric protocol. Symptoms improved rapidly during treatment, and neurological findings resolved. The patient returned to duty shortly thereafter with no recurrence of symptoms during long-term follow-up.
Operational Significance
This case highlights several important operational considerations:
Decompression sickness remains a real risk despite oxygen pre-breathing and adherence to established safety procedures
Symptoms may be delayed and initially subtle, requiring a high index of suspicion
Immediate access to hyperbaric treatment is critical for optimal outcomes, particularly in neurological cases
Remote and resource-limited environments require alternative solutions to fixed-facility evacuation models
The successful outcome demonstrates that definitive care for altitude-related DCS does not necessarily require long-range evacuation when appropriate portable capabilities are available.
SOS Review: Effectiveness of the Hyperlite 1 in Remote DCS Management
This case strongly illustrates the operational value of the SOS Hyperlite 1 as a field-deployable solution for managing decompression sickness in austere or geographically isolated environments.
Key observations from the case include:
Rapid access to treatment: The Hyperlite 1 enabled timely hyperbaric therapy without waiting for aircraft availability or specialist transport.
Reduced operational risk: Avoiding aeromedical evacuation eliminated the need to expose a symptomatic patient to further altitude changes.
Clinical effectiveness: Treatment resulted in prompt symptom resolution and full neurological recovery.
Operational efficiency: The use of a portable chamber avoided substantial financial and logistical costs associated with long-distance evacuation.
Flexibility and scalability: The system supported specialist consultation and standardized treatment protocols despite limited local resources.
Rather than functioning solely as contingency equipment, the Hyperlite 1 proved capable of delivering definitive care equivalent to fixed hyperbaric facilities. This reinforces its role as a critical component of medical planning for high-altitude aviation, airborne operations, and remote military installations.
Conclusion
This case demonstrates that even with modern preventative measures, decompression sickness remains an unpredictable and potentially serious risk in aviation operations. The availability of portable hyperbaric treatment fundamentally changes the response model—allowing rapid, effective care at the point of need.
Acknowledgments
The authors thank Lt. Col. Matthew Ramage for supervision of treatment.
This paper reflects the views of the authors and does not represent official views of the U.S. Air Force or affiliated medical groups.
You can read the whole study: https://pubmed.ncbi.nlm.nih.gov/33357273/